Replies to post #771437 on NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

I unfortunately have to agree that the low stock performance of NWBO is due to a lack of confidence of management and the actions they have taken so far.
If NWBO had a normally functioning management then they could probably look forward to the same revenue outlook performance as Iovance.
Bets for patients, shareholders and management is that NWBO would be bought for $ 5-7 billion after MHRA approval and normal functioning management will take over.